Evgeny Shlyakhto, Director General of the Almazov Centre, took an active part in the 22nd St. Petersburg International Economic Forum (SPIEF).
During the Forum on May 24, the Almazov Centre and Biocad signed a strategic partnership agreement to carry out joint research and develop antitumor cell vaccines. According to Prof. Shlyakhto, the plans for the year ahead are to progress to the stage of preclinical studies. The new vaccines may be used to treat cancer and autoimmune diseases.
The Almazov Centre was one of the four city’s leading medical organizations to sign the cooperation agreement with the St. Petersburg medical tourism agency. The medical tourism development program is supposed to create the framework for attracting an additional 325,000 visitors to the Russia’s northern capital annually.
Evgeny Shlyakhto highlighted that healthcare development, breakthrough technologies and public health protection have become the core focus of this year’s Forum. These issues received a great deal of attention not only at the medicine-specific sessions, but also at the dedicated session State Support as an Effective Tool for Securing Leadership in Innovation.